Mexco Energy vs Arcadia Biosciences
MXC and RKDA side by side. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How MXC and RKDA compare
Mexco Energy is the larger company, worth 41 times as much as Arcadia Biosciences ($19.2M against $466K).
Mexco Energy grew revenue faster over the last twelve months (−8.1% versus −12.2% for Arcadia Biosciences).
Mexco Energy keeps more of each dollar of sales as profit, with a net margin of 19.9% compared with −235% at Arcadia Biosciences.
Mexco Energy pays a dividend yielding 1.1%; Arcadia Biosciences does not pay one.
Mexco Energy scores higher on the StockData Score (13 against 6 for Arcadia Biosciences), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | MXC | RKDA |
|---|---|---|
| Size and price | ||
| Market cap | $19.2M | $466K |
| Share price | $9.40 | $0.194 |
| Change, 1 year | 3.3% | −95.0% |
| Change, 5 years | −11.4% | −99.7% |
| Beta (5Y) | 0.08 | 1.69 |
| Employees | 4 | 8 |
| StockData Score | ||
| Total score | 13 (better) | 6 |
| Valuation score | 2 (better) | 1 |
| Growth score | 0 | 0 |
| Performance score | 3 (better) | 0 |
| Health score | 6 (better) | 5 |
| Dividend score | 2 (better) | 0 |
| Valuation | ||
| P/E | 14.9× | – |
| P/S | 2.9× | 0.1× (better) |
| P/B | 0.9× | – |
| EV/EBITDA | 4.7× | – |
| Fair value | $11.47 | – |
| Margin of safety | 18.1% | – |
| Growth | ||
| Revenue growth (TTM) | −8.1% (better) | −12.2% |
| Revenue growth, 5Y average | 18.6% (better) | −9.6% |
| Net income growth (TTM) | −23.7% | – |
| EPS growth (TTM) | −22.2% | – |
| EPS growth, 5Y average | 51.1% | – |
| Profitability | ||
| Gross margin | – | 34.6% |
| Operating margin | 19.4% (better) | −80.1% |
| Net margin | 19.9% (better) | −235% |
| Return on equity | 6.7% | – |
| Return on invested capital | 5.6% | – |
| Financial health | ||
| Debt / equity | 0.00 | – |
| Interest coverage | 290× | – |
| Current ratio | 6.16 (better) | 3.49 |
| Altman Z-score | 7.54 (better) | −69.78 |
| Piotroski F-score | 6 (better) | 3 |
| Dividends and buybacks | ||
| Dividend yield | 1.1% | – |
| Payout ratio | 15.7% | – |
| Years of dividend growth | 0 | – |
| Shareholder yield | 1.1% (better) | 0.00% |
| Ownership | ||
| Held by institutions | 8.9% | 8.8% |
| Held by insiders | 1.5% | 1.4% |
| Insider net buying, 12 months | −$70.4K | – |
| Short interest, % of float | 0.21% | 4.9% |
Go deeper
- MXC stock overview
- MXC income statement
- MXC valuation and score
- RKDA stock overview
- RKDA income statement
- RKDA valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.